Novo Nordisk
2025.09.20
07:57
Novo Nordisk-backed biopharmaceutical company MapLight files for US IPO
On September 19th, local time, MapLight Therapeutics, a clinical-stage biopharmaceutical company backed by Novo Nordisk, filed for an IPO in the United States. The filing shows that the company's lead product candidates include two drugs for the treatment of schizophrenia and Alzheimer's disease psychotic disorder (ADP).
2025.09.19
03:20
Sources: Novo Nordisk (NVO.N) has cut its U.S. sales team for obesity and diabetes education for healthcare providers.
2025.09.18
21:31
Novo Nordisk (NVO.N) rose 5.5% after its study showed that the oral version of Wegovy achieved significant weight loss in late-stage trials.
20:10
Novo Nordisk (NVO.N) rose more than 7% in pre-market trading, on track for its best single-day performance since March 2024.
17:20
Novo Nordisk's US stock price rose nearly 5% in pre-market trading
Novo Nordisk's US stock rose nearly 5% in pre-market trading. Novo Nordisk's product director said semaglutide has significant advantages over rival Eli Lilly's obesity drug.
17:19
Novo Nordisk (NVO.N) continued to rise in pre-market trading, currently up 4.7%, after the company released results of a study on semaglutide.
16:49
Novo Nordisk (NVO.N): Semaglutide can reduce the risk of myocardial infarction and stroke by 25%, and is associated with a 25% reduction in the overall risk of major adverse cardiovascular events such as myocardial infarction, stroke, hospitalization for unstable angina or heart failure, and death.
05:13
Novo Nordisk (NVO.N): The 25 mg oral version of semaglutide showed improvements in the ability to perform daily physical activities and cardiovascular risk factors. The safety and tolerability profile of oral semaglutide was consistent with that of Wegovy for injection.
05:11
Novo Nordisk (NVO.N) has submitted a new drug application for approval, which will be reviewed by the U.S. Food and Drug Administration (FDA) before the end of the year.
05:11
Novo Nordisk's (NVO.N) oral version of its weight loss drug Wegovy is reportedly approaching the effectiveness of its injectable version in weight loss trials.
05:09
In a newly published study, Novo Nordisk's (NVO.N) oral semaglutide 25 mg (WEGOVY® tablets*) achieved a 16.6% weight loss in obese people.
2025.09.17
17:59
Novo Nordisk (NVO.N): Trials of semaglutide for Alzheimer's disease are "like a lottery."
17:44
Novo Nordisk (NVO.N): The company is ready to fully launch oral semaglutide in the United States early next year.
2025.09.10
16:00
Novo Nordisk: Layoffs will not have an impact on sales and production in the short term.
15:57
Novo Nordisk: Oral semaglutide for obesity is under review by the U.S. Food and Drug Administration (FDA), and the announcement about layoffs does not affect the application.
Load More
Email Subscription
Newsletters and emails are now available! Delivered on time, every weekday, to keep you up to date with North American business news.
Weekly Highlights
Musk: XAI will certainly raise funds in the next few months, but not now

2025-09-20

Nvidia (NVDA.O) fell further, dropping nearly 3%.

2025-09-17

SoftBank and OpenAI's AI joint venture in Japan is severely delayed, with an update now expected in November.

2025-09-18

HGTECH's 3.2T NPO products are used by leading industry customers

2025-09-24

Alipay's two operating entities have completed the name change

2025-09-19

ASIA TECH WIRE

Grasp technology trends

Download